| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2cureX AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.024 |
| 52 Week High | kr0.64 |
| 52 Week Low | kr0.018 |
| Beta | 0.68 |
| 1 Month Change | -24.69% |
| 3 Month Change | -85.21% |
| 1 Year Change | -95.67% |
| 3 Year Change | -98.66% |
| 5 Year Change | -98.56% |
| Change since IPO | -97.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QE | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 24.5% | -5.0% | -2.0% |
| 1Y | -95.7% | -13.6% | -0.3% |
Return vs Industry: 2QE underperformed the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: 2QE underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 2QE volatility | |
|---|---|
| 2QE Average Weekly Movement | 28.9% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QE's share price has been volatile over the past 3 months.
Volatility Over Time: 2QE's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 14 | Kenneth Johansen | www.2curex.com |
2cureX AB (publ) operates as a medtech company in Europe. The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers.
2cureX AB (publ) Fundamentals Summary
| 2QE fundamental statistics | |
|---|---|
| Market cap | €599.28k |
| Earnings (TTM) | -€2.66m |
| Revenue (TTM) | €254.00k |
2.4x
P/S Ratio-0.2x
P/E RatioIs 2QE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QE income statement (TTM) | |
|---|---|
| Revenue | kr2.95m |
| Cost of Revenue | kr10.83m |
| Gross Profit | -kr7.89m |
| Other Expenses | kr22.93m |
| Earnings | -kr30.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -1.75 |
| Gross Margin | -267.63% |
| Net Profit Margin | -1,045.78% |
| Debt/Equity Ratio | 0% |
How did 2QE perform over the long term?
See historical performance and comparison